Individual coverage health reimbursement arrangement (ICHRA)-focused deals nudged L&H deal count upward, in part driving the highest deal share among US-based insurtechs since Q3’17.

Below, we break down the key takeaways from this quarter’s report, including:

• Quarterly insurtech deal count dips below 100 again
• Funding to P&C insurtechs plummets from Q2’21 peak
• $100M+ mega-round deals lead to a surge in L&H insurtech funding
• ICHRA startups capture nearly 20% of insurtech funding
• US-based startups raise 3 in 5 global insurtech deals

Download the full report to access comprehensive data and charts on the evolving state of insurtech.

Quarterly insurtech deal count dips below 100 again

Insurtech deal count fell 9% quarter-over-quarter (QoQ), from 100 deals in Q1’25 to 91 in Q2’25. This decrease mirrors the broader venture environment, which also saw QoQ deal count decline by the same percentage.

Insurtech funding fell 21% QoQ, from $1.4B in Q1’25 to $1.1B in Q2’25 — also in line with the broader venture environment (-24% QoQ). However, unlike the rest of venture, insurtech has not experienced an AI-driven funding boom in recent quarters. The median venture deal size reached a new high of $3.5M in 2025 YTD, largely due to AI, while the median insurtech deal size has fallen by 19% to $4.2M over the same period.

Explore the top 20 AI agent startups by revenue

Future implication: Given investors’ appetite for billion-dollar deals, insurance incumbents should prepare for potential disruption if an AI-focused insurtech secures major funding.

Funding to P&C insurtech falls 89% from Q2’21 peak 

P&C insurtech funding plummeted from $1.2B in Q1’25 to $0.4B in Q2’25, falling well below the quarterly average of $0.8B over the past 2 years. As a result, P&C insurtech funding reached an 8-year low for the quarter (Q3’17 was the last quarter with less P&C insurtech funding).

The decline in P&C insurtech funding comes as no P&C insurtechs raised a Series D+ deal in Q2’25. Comparatively, 3 P&C insurtechs raised $100M+ mega-rounds across Series D+ deals in Q1’25.

P&C insurtech deal count also declined, falling from 72 in Q1’25 to 57 in Q2’25. Just 5 startups raised over half of the quarter’s P&C insurtech funding:

• Ledgebrook, a professional liability MGA ($65M Series C)
• Marshmallow, an auto insurer ($45M Series B)
• Steadily, a landlord insurer ($30M Series C)
• Orus, a small business insurance broker ($29M Series B)
• Reserv, a third-party administrator ($25M Series B)

Even so, the P&C insurtech space did see its first IPO since Q2’24: Florida-based home insurer Slide Insurance completed its IPO at a $2.1B valuation.

Check out Ledgebrook, Reserv, and more 2024 Insurtech 50 winners

Future implication: Despite the broader P&C funding decline, 3 of the top 5 P&C insurtech deals by funding amount in Q2’25 went to startups focused on small and midsize businesses (SMBs) — signaling that targeted growth opportunities within this segment remain attractive to investors.

$100M+ mega-round deals lead to a surge in L&H insurtech funding

L&H insurtech funding surged from $0.2B in Q1’25 to $0.7B in Q2’25, well above the quarterly average of $0.4B over the past 2 years.

Eight of the quarter’s top 11 deals went to L&H insurtechs, including both of the quarter’s $100M+ mega-round deals:

• Gravie, a late-stage benefits platform ($144M Series G, and later amended to $150M in a filing on July 9)
• Bestow, a former insurer that has since pivoted to become a software provider ($120M Series D)

L&H insurtechs raised 32 deals in Q2’25, an increase from 28 in the quarter prior. Unlike P&C insurtech, the median L&H insurtech deal size ($6.0M) is up in 2025 YTD.

69% of L&H insurtech deals went to US-based companies, the highest amount since Q3’15, underscored by a focus on health benefits across the US market.

In addition, L&H insurtech saw its first unicorn since Q2’22 and its first IPO since Q3’22:

• Chapter, a Medicare navigation platform, became the quarter’s only new insurtech unicorn after raising its $75M Series D round at a $1.5B valuation.
• Xiaoyusan Insurance, a broker focused on diversified life and health products, went public.

CBI customers: Use our agents to uncover insights for Chapter

Future implication: As nearly half of the quarter’s top deals by funding amount went to health and benefits-focused startups, insurers should prioritize expanding employer-focused sales channels for the upcoming open-enrollment season.

ICHRA startups capture nearly 20% of insurtech funding

The US federal government established ICHRA plans in 2019, spurring commercial traction in recent years. Notably, an ICHRA platforms market has since emerged, with 5 startups raising $234M in equity funding across 5 deals in Q2’25:

• Gravie ($144M, with participation from Atlantic Vantage Point)
• Thatch ($40M, with participation from ADP Ventures and SemperVirens Venture Capital)
• Venteur ($20M, led by American Family Ventures)
• Zorro ($20M)
• zizzl health ($10M)

An ICHRA is an alternative to traditional employer-selected health plans in the US, where employers instead allocate money for their employees to select their preferred qualified plan individually. ICHRA startups facilitate these payments, providing a central platform for benefits managers to administer their company’s ICHRA program.

The ICHRA platforms market is seeing favorable traction, evidenced by widespread increases in Mosaic score — measuring the overall health and growth potential of private companies — among companies assessed.

Most of these companies — Thatch, Gravie, Venteur, Remodel Health, Take Command Health, Zorro, StretchDollar, and BenefitBay — have Mosaic scores in the top 5% of all private companies tracked by CB Insights.

CBI Customers: Check out leaders in our ICHRA platforms market

Future implication: Health insurers have the potential to increase enrollment by enhancing distribution channels to engage individuals employed by SMBs using ICHRAs.

US-based startups raise 3 in 5 global insurtech deals

60% of Q2’25 insurtech deals went to US-based startups — an 8-year high. Q3’17 was the last quarter to see a larger deal share among US-based startups (61%).

The increase was attributable to slight deal share increases across both L&H and P&C insurtech (from 68% to 69% and from 53% to 56%, respectively).

Within the US, Silicon Valley and the New York City metro areas led in Q2’25 insurtech deals — 11 and 9, respectively.

Europe-based startups raised 21% of Q2’25 insurtech deals: 6 of those deals went to France-based startups, and 5 went to UK-based startups.

Check out the top 50 venture investors in France

Future implication: US insurtech deal share has increased each quarter since Q3’24, so companies should evaluate growth opportunities in global markets with less insurtech presence (i.e., less competition).

MORE INSURTECH RESEARCH FROM CB INSIGHTS

• 100 real-world applications of genAI across financial services and insurance
• Insurance’s new frontier: 3 innovation imperatives for 2025 and beyond
• Our 6 predictions for the insurance space in 2025

The post State of Insurtech Q2’25 Report appeared first on CB Insights Research.

Many of the world’s most influential financial services firms — like Allianz, J.P. Morgan, and Mastercard — have taken concrete action to adopt genAI technology.

The genAI adoption efforts have shaped 2 years’ worth of corporate strategy, unveiling key priorities — from the rise of agentic commerce to customer service copilots — across the competitive landscape.

Using CB Insights data, we identified and analyzed 100 real-world applications of genAI from 69 companies across banking, insurance, and payments.

Download the book to explore all 100 applications, and read on for 5 key takeaways and a breakdown of our methodology.

Key takeaways

1. Cross-functional platforms are now table stakes.

24% of applications center on deploying general-use genAI platforms to employees.

Prominent firms like BBVA have established enterprise-wide genAI capabilities across their organizations (typically via enterprise-wide deployments of platforms like Microsoft Copilot or ChatGPT). Early adopters — like Klarna, which shared in May 2024 that 87% of its employees are using OpenAI technology — now have over a year of genAI operational experience at scale, which can guide the development of more complex applications in the future.

Looking forward, financial services firms without a plan to provide genAI access to employees risk competitive disadvantage. Over the past 2 years, simply providing genAI capabilities to employees has shifted from cutting-edge innovation to standard operations.

2. Microsoft and OpenAI permeate the adoption landscape.

33% of applications analyzed disclose involvement from either Microsoft or OpenAI.

Microsoft and OpenAI (in which Microsoft has significantly invested) overwhelmingly permeate the landscape of genAI applications analyzed. Many of these applications anchor on foundational capabilities, from which organizations can build more complex applications and agents. Anthropic, Amazon Web Services, and Google Cloud follow a similar deployment pattern across multiple companies in the sector.

Looking forward, financial services firms should prepare for increasingly blurred “build, buy, or partner” decisions. The prevalence of genAI model developers (like OpenAI and Anthropic) and big tech partners (like Microsoft and Google) provide financial services executives with more flexibility to customize their tech solutions than what has traditionally been the case with many point-solution providers.

3. Emerging genAI vendors face a fierce competitive landscape.

Median Mosaic Scores among genAI startups analyzed are in the top 3% globally.

The 100 analyzed genAI applications include engagement from 25 startups as tech vendors, ranging from pre-seed companies like Twin — which offers an agent for invoice collection — to late-stage giants like Anthropic. These startups have a median CB Insights Mosaic Score — which measures the overall health and growth potential of private companies — of 732 out of 1,000, as of July 30, 2025.

Looking forward, financial services firms should prepare for increasingly capable tech vendors seeking to sell their genAI products. These vendors must exhibit a clear advantage over the alternative of building in-house solutions.

4. Customer-facing genAI will become increasingly prevalent.

16% of applications center on customer engagement & self-service capabilities.

Firms like ING, Wells Fargo, and Truist show that customer-facing genAI assistants are capable of powering millions of customer interactions. Customer-facing genAI deployment will accelerate as companies like Mastercard, Visa, and PayPal deploy applications centered on “agentic commerce,” where customers can autonomously shop and complete transactions with AI payments agents.

Looking forward, financial services firms need to develop a gameplan for how they will engage customers with agentic AI. The market opportunities for enterprise agents and copilots are growing, so customer-facing applications will quickly emerge.

5. Impact is now tangible, but success definitions remain elusive.

Only 30% of applications disclose quantitative tangible impact from deployment.

Most of the application sources analyzed lack disclosure of tangible impact (i.e., numbers, percentages, or figures to quantify effectiveness). Among the impact metrics that are available, the top-cited focus on operational considerations like call-handle times.

Looking forward, any financial services firm has the opportunity to define “what good genAI adoption looks like” across the sector. The lack of clear success definitions creates an opportunity for financial services firms to stand out among peers.

Methodology

We used CB Insights’ Business Graph — including data points like Dealmaking, Business Relationships, Earnings Transcripts, and Media Mentions — and third-party company releases to identify 100 real-world genAI applications across banking, insurance, and payments. These applications were disclosed between July 2023 and April 2025.

Then, using CB Insights’ Team of Agents, we analyzed these applications across 10 categories. Applications are detailed based on disclosure date, and are not exhaustive of a given company’s genAI initiatives. Applications and categorizations are not mutually exclusive or exhaustive of activity within their respective industries.

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post 100 real-world applications of genAI across financial services and insurance appeared first on CB Insights Research.

Insurtech does not exist in a vacuum, and the broader venture environment is centered on AI funding. In Q1’25, OpenAI raised nearly 31 times the total funding of all insurtechs combined, underscoring where capital is flowing.

AI capabilities are poised to reshape the future of insurance — whether through 100-day-old startups or 100-year-old incumbents adapting to a new competitive reality.

Download the full report to access comprehensive data and charts on the evolving state of insurtech.

Key takeaways from the report include:

• Insurtech dealmaking increases for the first time in a year. Global insurtech deal count increased 17% quarter-over-quarter (QoQ), from 83 in Q4’24 to 97 in Q1’25. Property & casualty insurtech drove the increase, from just 51 deals — a near 8-year low — in Q4’24 to 70 in Q1’25.
• Median insurtech deal size tumbles 35% in 2025 YTD (year to date) to $4.0M. The median insurtech deal size has not been lower since 2019 ($3.4M). The decline stands out because median deal sizes across the broader venture environment rose 17% YTD to $3.5M, while insurtech’s fell.
• Early-stage insurtech funding reaches a nearly 8-year low — $179M. Early-stage insurtech funding fell 35% year-over-year (YoY) from $277M in Q1’24.
• Late-stage insurtech dealmaking paints a cautious growth picture. The 7 insurtechs that raised Series D+ deals in Q1’25 saw median headcount growth of just 3% over the past 12 months — far lower than insurtechs raising at earlier stages.
• Silicon Valley sees 1 in 5 global insurtech deals. Silicon Valley’s share of global insurtech equity deals has nearly doubled YoY, from 10.9% in Q1’24 to 21.9% in Q1’25. Funding to Silicon Valley-based insurtech increased to $0.3B — the highest level since Q4’23 ($0.4B).

Insurtech dealmaking increases for the first time in a year

Insurtech deal count increased 17% QoQ, from 83 deals in Q4’24 to 97 in Q1’25 — a reversal of the broader venture trend, where deal count declined 7% over the same period.

The rebound was driven by property & casualty insurtech, which jumped from just 51 deals — a near 8-year low — in Q4’24 to 70 in Q1’25. Meanwhile, life & health insurtech saw deal count dip to 27 in Q1’25.

This increase in activity followed an abnormally weak Q4, when funding had fallen to $0.8B. In Q1’25, insurtech funding surged 63% to $1.3B — slightly above the 10-quarter average of $1.2B. Notably, insurtech was the only fintech vertical to post a funding gain this quarter.

Nearly $400M toward three $100M+ mega-round deals contributed to the broader funding rebound:

• Quantexa, a data management and financial crime prevention platform, raised a $175M Series F deal.
• Openly, a homeowners-focused general agency and program administrator, raised a $123M Series E deal.
• Instabase, an AI platform for unstructured data, raised a $100M Series D deal.

Explore Quantexa’s $2.6B AI-driven rise with the full scouting report

Future implication: These mega-rounds signal investors’ readiness to write large checks for select insurtechs — even in a cautious funding environment. For incumbents, this underscores the importance of tracking well-capitalized startups that could pose competitive threats through 2025.

Median insurtech deal size tumbles in Q1’25

Half of the quarter’s top 10 insurtech deals went to AI-centered startups: Quantexa, Instabase, Nirvana, Taktile, and Naked. But unlike the broader venture market, insurtech lacked the depth of large-dollar AI deals needed to lift the median.

While the average insurtech deal size ticked up 6% to $15.8M in 2025 YTD, the median insurtech deal size tumbled from $5.4M in 2024 to $4.0M — its lowest point since 2019 ($3.4M). This trend diverged from the broader venture environment, where a spike in $100M+ mega-rounds pushed medians higher.

Early-stage insurtech saw a similar dynamic, with median deal sizes declining to $3.0M in 2025 YTD — even as the broader venture landscape saw an increase, from $2.0M in 2024 to $2.8M. Fertility-focused platform Gaia raised the largest early-stage insurtech deal in Q1’25 ($15M Series A).

Track 2.5K+ insurtech companies

Future implication: Smaller check sizes could give incumbent insurers an opening to partner with capital-constrained insurtechs — potentially securing more favorable terms and early access to emerging tech that would be harder to land in a hotter market.

Early-stage insurtech funding reaches a nearly 8-year low

Early-stage insurtech startups raised just $178.5M across 56 deals in Q1’25 — the lowest total since Q4’16 ($162.8M). Funding has dropped sharply over the past year, falling 35% from Q1’24.

Early-stage insurtech deal share has also tumbled over the past few years. In 2022, 71% of deals went to early-stage insurtechs, while in 2025 YTD, it was just 58%.

Still, the quarter delivered one notable early-stage highlight: AI claims platform Assured became just the second new insurtech unicorn since Q4’23. The startup raised an undisclosed Series A round at a $1B valuation, backed by ICONIQ Capital and Kleiner Perkins. 

Assured also ranks in the global top 4% of companies for hiring momentum and is actively prioritizing genAI-focused hires:

CBI customers: Explore all of Assured’s Hiring Insights

Future implication: The sustained drop in early-stage insurtech funding risks shrinking the industry’s future innovation pipeline. To stay ahead, insurance execs should prioritize identifying and building relationships with promising startups now — before competition for a smaller pool of standouts intensifies.

Late-stage insurtech dealmaking paints a cautious growth picture

The 7 insurtechs that raised Series D+ rounds in Q1’25 posted median 12-month headcount growth of just 3% — significantly lower than their earlier-stage peers. Only one of them — insurance customer communication platform Ushur — saw double-digit growth over the same period.

Ushur is also the only insurtech among the 7 with an above-average M&A probability within the next 2 years. This signals a potential standstill in the late-stage insurtech market, especially as the IPO pipeline remains frozen — just 2 insurtechs have gone public since 2023.

CBI customers: Ask ChatCBI a question about Ushur’s Scouting Report

Future implication: With just 3% median headcount growth, late-stage insurtechs are showing signs of stagnation. In a market where public investors expect clear growth momentum, more of these companies may be pushed toward M&A exits — often at compressed valuations.

Silicon Valley sees 1 in 5 global insurtech deals

Silicon Valley has now seen 2 consecutive quarters of elevated insurtech dealmaking. The share of global insurtech deals to Silicon Valley-based startups nearly doubled YoY, rising from 10.9% in Q1’24 to 21.9% in Q1’25. Comparatively, 9% of deals across the broader venture environment went to Silicon Valley-based companies in Q1’25.

2 of the quarter’s top 5 insurtech deals went to Silicon Valley-based insurtechs: Instabase and Nirvana ($80M Series C). As a result, Silicon Valley’s insurtech funding in Q1’25 increased to $0.3B — the highest level since Q4’22 ($0.4B). By comparison, Europe’s insurtech market saw $0.4B in funding across 26 deals in Q1’25, slightly edging out Silicon Valley’s total.

Silicon Valley also saw a major insurtech exit in Q1’25: Munich Re announced its acquisition of Palo Alto-based Next Insurance — one of insurtech’s most-promising startups — at a $2.6B valuation.

Future implication: As the world’s premier tech ecosystem, Silicon Valley remains a leading indicator for insurtech innovation. Insurance executives should track tech talent migration into insurtech as a signal of where future competitive threats may emerge.

MORE INSURTECH RESEARCH FROM CB INSIGHTS

• Our 6 predictions for the insurance space in 2025
• How genAI is reshaping the insurance value chain
• Insurtech 50: The most promising insurtech startups of 2024

The post State of Insurtech Q1’25 Report appeared first on CB Insights Research.

Just 113 investors made at least 2 equity insurtech investments during the year — a 72% drop from the high of 406 investors in 2021. As a result, insurtech dealmaking dropped to 362 deals, the lowest annual total since 2016.

Download the full report to access comprehensive data and charts on the evolving state of insurtech.

Key takeaways from the report include:

• Insurtech dealmaking and funding continue to decline. Deal count fell 28% year-over-year (YoY) to 362 deals in 2024, while funding dropped 4% to $4.5B. Insurtech deals and funding are both at recent lows.
• Quarterly funding to P&C insurtechs is in the gutter. P&C funding dropped 43% quarter-over-quarter (QoQ) to $0.4B in Q4’24 — a 7-year low — with annual funding also declining to $2.6B. The year’s 2 largest deals in P&C went to AI-focused startups Altana AI and Akur8, highlighting investors’ appetite for specialized AI opportunities.
• Silicon Valley is dethroned as insurtech’s funding capital. Silicon Valley’s share of global insurtech funding dropped dramatically from 20% in 2023 to 10% in 2024, surpassed by New York at 15%. This was the first time since 2018 that Silicon Valley wasn’t No. 1.
• Early-stage insurtechs raise record-high deal sizes. The median early-stage insurtech deal size surged 52% YoY to $3.8M in 2024 — outpacing the broader venture landscape — as investors concentrate on a more selective group of innovators.
• Recently funded insurtechs show stronger business fundamentals and more efficient growth trajectories. Insurtechs that raised funding in 2024 have grown employee headcounts by a median of 20% over the last 12 months, far surpassing the 3% growth among those that raised during the funding boom of 2021.

Insurtech dealmaking and funding continue to decline

Insurtech deal count fell 28% YoY, from 500 deals in 2023 to 362 in 2024. The decline outpaced the broader venture environment, which saw deal count fall 19% YoY. 2024 was the worst year for insurtech dealmaking since 2016 (328 deals).

Deal volume among leading investors has also decreased. The number of investors that made 5 or more equity insurtech investments has fallen from 57 in 2021 to just 7 in 2024. Those that remain active now operate in a more favorable environment due to reduced competition across the marketplace.

Insurtech funding declined in 2024 as well, though by only 4% YoY. 

CBI customers: Track 2.5K+ insurtech companies

Quarterly funding to P&C insurtechs is in the gutter

Q4’24 marked a 7-year low for P&C insurtech funding, which fell 43% QoQ to $0.4B. The decline caused broader insurtech funding to halve QoQ, from $1.4B in Q3’24 to $0.7B in Q4’24.

P&C deal count also fell 10% QoQ to 45 in Q4’24, the lowest level since Q2’16.

Annual P&C insurtech funding declined to $2.6B in 2024, a 7-year low, underscored by just 2 P&C insurtech startups raising $100M+ mega-round deals: Altana AI, which offers an AI-powered supply chain risk platform, and Akur8, an AI-powered pricing platform. Those deals signal appetite for specialized AI products for the insurance industry, coinciding with a global surge in AI funding to over $100B last year.

Comparatively, life & health insurtech saw an increase in annual funding and dealmaking. Funding increased 64% YoY to $1.8B in 2024, while deals ticked up from 126 in 2023 to 128 in 2024.

Silicon Valley is dethroned as insurtech’s funding capital

The share of global insurtech funding to Silicon Valley-based startups halved YoY, falling from 20% in 2023 to 10% in 2024. Comparatively, New York led the way with 15% of global insurtech funding share in 2024, more than doubling from 7% the year prior.

Silicon Valley is the world’s leading tech ecosystem, and venture-wide funding to the region’s startups soared last year amid a boom in AI investment. Given the ecosystem’s prominence, diminished insurtech activity in Silicon Valley could lead to missed opportunities for insurance-focused AI advancements.

See how Silicon Valley fared in the broader venture market

Early-stage insurtechs raise record-high deal sizes

The median insurtech deal size increased from $4.1M in 2023 to $5.2M in 2024.

The increase was fueled by early-stage insurtechs, which saw median deal size surge 52% YoY, from $2.5M in 2023 to $3.8M in 2024. The size and growth rate both beat out the broader venture environment, where early-stage deal size increased 17% YoY to $2.1M.

Combined with the broader decline in dealmaking, larger check sizes indicate that investors are concentrating their investments on fewer bets. For the insurance industry, this dynamic points to a slimmer insurtech landscape with fewer high-growth participants moving forward.

On the other hand, late-stage insurtech deal sizes declined 19% YoY from $40M in 2023 to $32.5M in 2024.

The decline coincides with a restricted exit environment: Insurtech M&A exits fell from 57 in 2023 to 35 in 2024. 

Nevertheless, notable exits include CCC Intelligent Solutions’s acquisition of EvolutionIQ in December at a valuation of $730M, as well as Applied’s purchase of Planck in July. Both acquisitions targeted genAI-enabled startups, signaling a broader appetite for genAI insurance offerings.

Recently funded insurtechs show stronger business fundamentals

Insurtechs that raised funding in 2024 are growing headcounts faster than other insurtechs, by a median of 20% over the last 12 months and 40% over the last 24 months.

Comparatively, median headcount growth among insurtechs that raised a funding round at the height of the funding boom in 2021 is marginal — just 3% over the last 12 months.

The higher growth rates of recently funded insurtechs suggest a new breed of companies with stronger fundamentals — they’re not only able to raise capital in a selective market but are also demonstrating more efficient growth than their 2021-funded counterparts.

By the same logic, investors and partners (like established brokers and carriers) should monitor the landscape for outliers that represent organic growth opportunities — such as insurtechs that haven’t raised funding in several years but continue to grow headcount at a steady clip.

See the fastest-growing insurtechs by headcount growth

MORE INSURTECH RESEARCH FROM CB INSIGHTS

• How genAI is reshaping the insurance value chain
• Insurtech 50: The most promising insurtech startups of 2024
• ITC Vegas 2024: Insurance is facing an AI inflection point
• Tech Transforming the World: The Game Changers Roundtable

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post State of Insurtech 2024 Report appeared first on CB Insights Research.